SecBot SecBot
8-K ·Filed Aug 5, 2026

MIRM

Mirum Pharmaceuticals, Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001759425-26-000044
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The raised revenue guidance is a clear positive, but the volixibat delay and GAAP EPS miss temper the outlook. Traders should watch for upcoming brelovitug Phase 3 data (Q3/Q4 2026) and the zilurgisertib PDUFA date (Sept 26, 2026) as key catalysts. The convertible note issuance strengthens the balance sheet but adds dilution risk.

DirectionMixed
Confidencehigh
Horizonweeks

Drugs in focus

MIRM drug pipeline →

brelovitug

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3 (completed)
Time to market
Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
Next catalyst
BLA filing · H1 2027

What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$94.12
T+0 close · Aug 5, 2026 · via day close
Latest settled
−9.69%
T+60 · $85.00
Vs SPY
−8.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $94.12entry
  2. T+1 · 3mo ago +6.94%α +6.33% · $100.65
  3. T+5 · 3mo ago +4.95%α +3.73% · $98.77
  4. T+20 · 3mo ago +6.92%α +6.32% · $100.63
  5. T+60 · 18d ago −9.69%α −8.01% · $85.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2M, a 38% YoY increase, and raised full-year guidance to $680M-$700M. However, GAAP EPS was -$1.06, a significant miss vs the -$0.75 consensus, driven by heavy R&D and SG&A spending. The volixibat NDA submission was delayed to H1 2027 after the FDA recommended a Phase 3 study, a key pipeline setback. The strong commercial performance and raised guidance are offset by the earnings miss and the volixibat delay, resulting in a mixed outlook.

Key Financial Metrics

EPS
−$1.06
est −$0.75 · -41.3%
Revenue
$176.2M
est $166.4M · +5.9% · +37.9% YoY
Rating
miss
Guidance
$680M-$700M
raised

Key Facts

  • Q2 2026 net product sales of $176.2M, up 38% YoY from $127.8M.
  • Full-year 2026 net product sales guidance raised to $680M-$700M from $660M-$680M.
  • GAAP net loss per share of -$1.06 vs consensus of -$0.75 (a miss).
  • Volixibat NDA submission for PSC delayed to H1 2027 after FDA recommended a Phase 3 study.
  • Issued $690M of 0.00% convertible senior notes due 2032 and settled $237.2M of 4.00% notes.
  • Cash and investments of $561.3M as of June 30, 2026.

Financial Impact

Revenue beat by $9.8M (+5.9%) vs $166.4M consensus; EPS missed by -$0.31 (-41.3%) vs -$0.75 consensus.

revenueepsguidancepipeline

Risk Factors

  • Volixibat NDA submission delay to H1 2027 after FDA requested a Phase 3 study.
  • GAAP EPS miss of -$1.06 vs consensus -$0.75, driven by high operating expenses.
  • Potential dilution from the $690M convertible note issuance.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759425-26-000044
Document: mirm-20260805.htm0001759425-26-000044
Document: 0001759425-26-000044-index-headers.html0001759425-26-000044
Document: 0001759425-26-000044-index.html0001759425-26-000044
Document: 0001759425-26-000044.txt0001759425-26-000044
8-K Data (Synthetic)0001759425-26-000044

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026